Literature DB >> 12670912

Characterization of sporadic colon cancer by patterns of genomic instability.

Ajay Goel1, Christian N Arnold, Donna Niedzwiecki, Dong K Chang, Luigi Ricciardiello, John M Carethers, Jeannette M Dowell, Linda Wasserman, Carolyn Compton, Robert J Mayer, Monica M Bertagnolli, C Richard Boland.   

Abstract

Colorectal cancer (CRC) can progress through two pathways of genomic instability: chromosomal (CIN) and microsatellite instability (MSI). We hypothesized that these two pathways are not always independent and that some tumors therefore show a significant degree of overlap between these two mechanisms. We classified 209 high-risk stage II and stage III sporadic CRCs based on their MSI status, using a National Cancer Institute-recommended panel of microsatellite markers, and also identified MSI-associated mutations of CRC target genes such as TGFbetaRII. Evidence for CIN was gathered by identifying loss of heterozygosity (LOH) events on chromosomal arms 1p, 2p, 3p, 5q, 17p, and 18q, which are regions harboring mismatch-repair and tumor-suppressor genes that are significant in CRC development. Results of all molecular markers tested were correlated with clinicopathological variables of the cohort, including treatment outcome. Of the 209 cases, 65% cancers were microsatellite stable, 21% were MSI-low, and 14% were MSI-high (MSI-H). Overall, 51% of the tumors had at least one LOH event, with most frequent chromosomal losses observed on 18q (72.5%), followed by 5q (22%), 17p (21%), and 3p (14%). Interestingly, we observed a significant degree of overlap between MSI and CIN pathways. Of 107 cancers with LOH events, 7 (6.5%) were also MSI-H, and of 30 cancers that were MSI-H, 7 (23.3%) also had one or more LOH events. We also found that 37.8% of microsatellite-stable cancers had no LOH events identified, thus comprising a subgroup of tumors that were not representative of either of these two pathways of genomic instability. Our data suggest that molecular mechanisms of genomic instability are not necessarily independent and may not be fully defined by either the MSI or CIN pathways.

Entities:  

Mesh:

Year:  2003        PMID: 12670912

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  92 in total

1.  Diagnosing Lynch syndrome: is the answer in the mouth?

Authors:  H K Roy; H T Lynch
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

2.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

3.  Clearing the air on smoking and colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  J Natl Cancer Inst       Date:  2010-06-29       Impact factor: 13.506

4.  Familial colorectal cancer type X syndrome: two distinct molecular entities?

Authors:  Inês Francisco; Cristina Albuquerque; Pedro Lage; Hélio Belo; Inês Vitoriano; Bruno Filipe; Isabel Claro; Sara Ferreira; Paula Rodrigues; Paula Chaves; Carlos Nobre Leitão; António Dias Pereira
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

5.  5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

Authors:  Rodrigo Jover; Thuy-Phuong Nguyen; Lucía Pérez-Carbonell; Pedro Zapater; Artemio Payá; Cristina Alenda; Estefanía Rojas; Joaquín Cubiella; Francesc Balaguer; Juan D Morillas; Juan Clofent; Luis Bujanda; Josep M Reñé; Xavier Bessa; Rosa M Xicola; David Nicolás-Pérez; Antoni Castells; Montserrat Andreu; Xavier Llor; C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-12-24       Impact factor: 22.682

6.  Clement Richard Boland, Jr., MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Clement Richard Boland
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

Review 7.  Infection, inflammation, and gastrointestinal cancer.

Authors:  C R Boland; M G Luciani; C Gasche; A Goel
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 8.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

Review 9.  Apoptotic pathways as a therapeutic target for colorectal cancer treatment.

Authors:  Aman M Abraha; Ezra B Ketema
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

10.  The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer.

Authors:  Do Youn Park; Hideo Sakamoto; Sandra D Kirley; Shuji Ogino; Takako Kawasaki; Eunjeong Kwon; Mari Mino-Kenudson; Gregory Y Lauwers; Daniel C Chung; Bo R Rueda; Lawrence R Zukerberg
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.